Abstract 302P
Background
DNA repair pathways are implicated both in carcinogenesis and progression of cancer. The genetically determined baseline expression level of DNA repair genes is associated with risk of cervical pre-cancer and cancer. In this study, we aim to evaluate expression level of one such DNA repair gene -Excision Repair Cross- Complementation Group 4 (ERCC4) and its correlation to various clinical and pathological parameters in cervical cancer in North Indian population.
Methods
Expression profiling of ERCC4 in 55 histopathologically confirmed cervical tumor biopsies and 25 control samples (hysterectomy) were done using Real time PCR(q-PCR), western blot analysis. Correlation analysis was done with different clinical and pathological parameters. ROC curve assessment was done to check the diagnostic utilities of the calculated data. One way ANOVA and t-test were used to calculate statistical significance using Graphpad PRISM 9.
Results
Relative fold change for mRNA expression analysis showed up-regulation of ERCC4 in 78.2% (n=43) patient biopsies, calculated by ΔΔct method. At translational level, the up regulation was around 52% (n=28). The up-regulations were significant with p value less than 0.05. Also, ERCC4, mRNA expression showed positive correlation with tumor stage and grade. Positive correlation was also observed in ERCC4 protein expression with respect to different age groups and histological status. High risk HPV-18 strain type was shown to be more influential in up regulating ERCC4 expression, both at transcriptional and translational level.
Conclusions
ERCC4 is significantly up-regulated at both transcriptional and translational levels in cervical cancer patient cohort, comprising of North Indian population. Higher expression of ERCC4 in tumor samples suggests its role as a potential diagnostic and/or prognostic marker in Ca Cervix.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Medical Sciences, BHU, Varanasi, India.
Funding
BHU under Institute of Eminence (IoE).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract